{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:43:17Z","timestamp":1781700197600,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Serum troponin levels correlate with the extent of myocyte necrosis in acute myocardial infarction (AMI) and predict adverse outcomes. However, thresholds of cardiac troponin elevation that could portend to poor outcomes have not been established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this cohort study, we characterized all cardiac troponin elevations\u2009&gt;\u20090.04\u00a0ng\/mL (upper limit of normal [ULN]) from patients hospitalized with an ICD-9\/10 diagnosis of AMI across our health system from 2012\u20132019. We grouped events into exponential categories of peak cardiac troponin and evaluated the association of these troponin categories with all-cause mortality, heart transplants, or durable left ventricular assist devices (LVAD). Patients with cardiac troponin\u2009&gt;\u200910,000\u2009\u00d7\u2009ULN were manually chart reviewed and described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 18,194 AMI hospitalizations with elevated cardiac troponin. Peak troponin was 1\u201310\u2009\u00d7\u2009ULN in 21.1%, 10\u2013100\u2009\u00d7\u2009ULN in 34.8%, 100\u20131,000\u2009\u00d7\u2009ULN in 30.1%, 1,000\u201310,000\u2009\u00d7\u2009ULN in 13.1%, and\u2009&gt;\u200910,000\u2009\u00d7\u2009ULN in 0.9% of patients. One-year mortality was 17\u201321% across groups, except in\u2009&gt;\u200910,000\u2009\u00d7\u2009ULN group where it was 33% (adjusted hazard ratio (99%CI) for\u2009&gt;\u200910,000\u2009\u00d7\u2009ULN group compared to all others: 1.86 (1.21, 2.86)). Hazards of one-year transplant and MCS were also significantly elevated in the\u2009&gt;\u200910,000\u2009\u00d7\u2009ULN group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Elevation in cardiac troponin levels post AMI that are\u2009&gt;\u200910,000\u2009\u00d7\u2009ULN was rare but identified patients at particularly high risk of adverse events. These patients may benefit from clarification of goals of care and early referral for advanced heart failure therapies. These data have implications for conversion to newer high-sensitivity cardiac troponin assays whose maximum assay limit is often lower than traditional assays.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-023-03168-0","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:25:12Z","timestamp":1679631912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Magnitude of troponin elevation in patients with biomarker evidence of myocardial injury: relative frequency and outcomes in a cohort study across a large healthcare system"],"prefix":"10.1186","volume":"23","author":[{"given":"Colleen K.","family":"McIlvennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Urra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Helmkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Messenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Raymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Ream","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bradley","family":"Oldemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrut V.","family":"Ambardekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"issue":"18","key":"3168_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1093\/eurheartj\/ehq251","volume":"31","author":"K Thygesen","year":"2010","unstructured":"Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31(18):2197\u2013204. https:\/\/doi.org\/10.1093\/eurheartj\/ehq251. Epub 2010 Aug 3 PMID: 20685679.","journal-title":"Eur Heart J"},{"issue":"18","key":"3168_CR2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. J Am Coll Cardiol. 2018;72(18):2231\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1038. Epub 2018 Aug 25 PMID: 30153967.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3168_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s0002-9149(99)00808-5","volume":"85","author":"RH Christenson","year":"2000","unstructured":"Christenson RH, Vollmer RT, Ohman EM, Peck S, Thompson TD, Duh SH, Ellis SG, Newby LK, Topol EJ, Califf RM. Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study. Group Am J Cardiol. 2000;85(5):543\u20137. https:\/\/doi.org\/10.1016\/s0002-9149(99)00808-5. PMID: 11078264.","journal-title":"Group Am J Cardiol"},{"issue":"4","key":"3168_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jcin.2008.04.010","volume":"1","author":"S Chia","year":"2008","unstructured":"Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008;1(4):415\u201323. https:\/\/doi.org\/10.1016\/j.jcin.2008.04.010. PMID: 19463339.","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"3168_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.283.3.347","volume":"283","author":"JH Alexander","year":"2000","unstructured":"Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbal\u00e1n R, Chierchia SL, Boland JB, Simoons ML, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA. 2000;283(3):347\u201353. https:\/\/doi.org\/10.1001\/jama.283.3.347. PMID: 10647797.","journal-title":"JAMA"},{"issue":"16","key":"3168_CR6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/archinte.165.16.1870","volume":"165","author":"MT Roe","year":"2005","unstructured":"Roe MT, Peterson ED, Li Y, Pollack CV Jr, Christenson RH, Peacock WF, Fesmire FM, Newby LK, Jesse RL, Hoekstra JW, et al. Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. Arch Intern Med. 2005;165(16):1870\u20136. https:\/\/doi.org\/10.1001\/archinte.165.16.1870. PMID: 16157831.","journal-title":"Arch Intern Med"},{"issue":"4","key":"3168_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/eurheartj\/ehaa885","volume":"42","author":"J Silvain","year":"2021","unstructured":"Silvain J, Zeitouni M, Paradies V, Zheng HL, Ndrepepa G, Cavallini C, Feldman DN, Sharma SK, Mehilli J, Gili S, et al. Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. Eur Heart J. 2021;42(4):323\u201334. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa885. Erratum in: Eur Heart J 2021;42(14):1443. PMID:33257958;PMCID:PMC7850039.","journal-title":"Eur Heart J"},{"issue":"6","key":"3168_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"TM Maddox","year":"2021","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772\u2013810. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.022. Epub 2021 Jan 11 PMID: 33446410.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"3168_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.amjcard.2010.06.050","volume":"106","author":"RA Byrne","year":"2010","unstructured":"Byrne RA, Ndrepepa G, Braun S, Tiroch K, Mehilli J, Schulz S, Sch\u00f6mig A, Kastrati A. Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2010;106(9):1212\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2010.06.050. Epub 2010 Sep 9 PMID: 21029815.","journal-title":"Am J Cardiol"},{"issue":"5","key":"3168_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.healun.2017.02.010","volume":"36","author":"J Baumwol","year":"2017","unstructured":"Baumwol J. \u201cI Need Help\u201d-A mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017;36(5):593\u20134. https:\/\/doi.org\/10.1016\/j.healun.2017.02.010. Epub 2017 Feb 10 PMID: 28258792.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"3168_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.104.478347","volume":"112","author":"DE Cutlip","year":"2005","unstructured":"Cutlip DE, Kuntz RE. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation. 2005;112(6):916\u201322 PMID: 16092153.","journal-title":"Circulation"},{"issue":"1","key":"3168_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","volume":"21","author":"P Paolisso","year":"2022","unstructured":"Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, Sardu C, Mileva N, Foa A, Armillotta A, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21(1):77.","journal-title":"Cardiovasc Diabetol"},{"issue":"26","key":"3168_CR13","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1056\/NEJMoa1803377","volume":"380","author":"JT Neumann","year":"2019","unstructured":"Neumann JT, Twerenbold R, Ojeda F, S\u00f6rensen NA, Chapman AR, Shah ASV, Anand A, Boeddinghaus J, Nestelberger T, Badertscher P, et al. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med. 2019;380(26):2529\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1803377. PMID: 31242362.","journal-title":"N Engl J Med"},{"issue":"10","key":"3168_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11886-017-0904-4","volume":"19","author":"VC Vasile","year":"2017","unstructured":"Vasile VC, Jaffe AS. High-sensitivity cardiac troponin for the diagnosis of patients with acute coronary syndromes. Curr Cardiol Rep. 2017;19(10):92. https:\/\/doi.org\/10.1007\/s11886-017-0904-4. PMID: 28840515.","journal-title":"Curr Cardiol Rep"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03168-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:26:30Z","timestamp":1679631990000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03168-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3168"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03168-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were approved by the Colorado Institutional Review Board and were conducted in accordance with the principles outlined in the Declaration of Helsinki. The need for written informed consent was waived by the Colorado Institutional Review Board due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Health Data Compass is a joint initiative of the University of Colorado Anschutz Medical Campus, CU Medicine, UCHealth, and Children's Hospital Colorado. Dr. Allen receives grant funding from American Heart Association, National Institutes of Health, and the Patient- Centered Outcomes Research Institute; and received consulting fees from Abbott, ACI Clinical, Amgen, Boston Scientific, Cytokinetics, and Novartis. All other authors report no conflicts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}